Valuation: Vectus Biosystems Limited

Market Cap 6.53M 4.54M 4.04M 3.74M 3.41M 6.43M 431M 44.99M 17.64M 225M 17.05M 16.69M 717M P/E 2025
-1.2x
P/E 2026 4.45x
Enterprise Value 3.56M 2.48M 2.2M 2.04M 1.86M 3.5M 235M 24.53M 9.62M 123M 9.29M 9.1M 391M EV / Sales 2025
4.35x
EV / Sales 2026 1.71x
Free-Float
49.49%
Yield 2025 *
-
Yield 2026 -
Current month-4.55%
1 month-12.50%
3 months-40.00%
6 months-30.00%
Current year-41.67%
1 week 0.1
Extreme 0.105
0.1
1 month 0.1
Extreme 0.1
0.15
Current year 0.09
Extreme 0.09
0.22
1 year 0.09
Extreme 0.09
0.46
3 years 0.04
Extreme 0.037
0.46
5 years 0.04
Extreme 0.037
2.2
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 07/05/2026
Corporate Secretary - 09/07/2015
Director TitleAgeSince
Director/Board Member - 12/12/2005
Chairman - 31/08/2018
Director/Board Member - 20/12/2024
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+41.89%-70.83% 4.52M
-6.60%-8.56%+42.79%+64.16% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.53%+2.70%+29.72%+34.13% 44.61B
-1.34%+4.12%+16.05%+112.18% 42.53B
-5.97%-6.22%+258.21%+421.57% 40.57B
+6.53%+8.02%+15.74%+53.94% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-2.76%-9.54%-16.53%-9.55% 22.66B
Average -1.66%-0.80%+43.18%+70.05% 37.97B
Weighted average by Cap. -2.43%-0.10%+44.74%+90.24%

Financials

2025 2026
Net sales 478K 333K 296K 274K 249K 471K 31.58M 3.3M 1.29M 16.48M 1.25M 1.22M 52.53M 2.77M 1.93M 1.71M 1.59M 1.44M 2.72M 183M 19.07M 7.48M 95.35M 7.23M 7.07M 304M
Net income -1.78M -1.24M -1.1M -1.02M -927K -1.75M -117M -12.25M -4.8M -61.24M -4.64M -4.54M -195M 1.56M 1.08M 964K 894K 813K 1.53M 103M 10.74M 4.21M 53.71M 4.07M 3.98M 171M
Net Debt -50.99K -35.48K -31.54K -29.23K -26.59K -50.18K -3.37M -351K -138K -1.76M -133K -130K -5.6M -2.97M -2.07M -1.84M -1.7M -1.55M -2.92M -196M -20.47M -8.02M -102M -7.76M -7.59M -326M
Projected Income Statement - Annual - Vectus Biosystems Limited
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
12/10/26 A$0.1050 0.00% 136,700
09/10/26 A$0.1050 0.00% 7